Micro Imaging Technology is pleased to Announce the Acquisition of Cellmyx
Micro Imaging Technology is pleased to Announce the Acquisition of Cellmyx
Publish Date: 2026-06-05 08:45:00
Source Domain: www.prnewswire.com
IRVINE, Calif., June 5, 2026 /PRNewswire/ — Micro Imaging technology, Inc. (“MIT”) a California-based public company symbol (MMTC), is pleased to announce the acquisition of Cellmyx, a great addition to MIT’s portfolio of companies in the “Aesthetic, Cosmetic Surgery and Regenerative Medicine Space.”
For 25 years the name “Millennium Medical Technologies Inc.” DBA: Cellmyx, has been synonymous with quality and is known throughout the cosmetic surgical industry for product dependability. Company founder Greg Miles has strived to manufacture top of the line medical tools that run the gamut of application, aesthetics, and beyond. Regenerative intelliFat injectables offer a new frontier of research and invention, and Cellmyx is poised to lead the way in this exciting discipline.
The acquisition of Cellmyx is complementary to the acquisition of SaltMed/SaltFacial which closed in late December 2025. The combination of these two companies strengthens the ability to expand and manufacture its existing products not only nationally but also worldwide. Cellmyx, is an authority and leader on autologous adipose grafting and transfer, with a specialty in medical technologies for orthopedic physicians, pain management, and regenerative medicine, which received clearance in early 2023 for intelliFat® BOD™ from the U.S. Food and Drug Administration (FDA) 510(k) (Ref.# K210528) ISO 13485#0136711 and MDSAP#0136710 Certification.
FDA has cleared the way for this groundbreaking new medical appliance and technology for use in orthopedic, plastic, and cosmetic surgery procedures. IntelliFat® BOD™ successfully uses a patient’s own body fat, clinically referred to as adipose tissue, to aid in patient recovery and healing in all parts of the body (joint and ligament repair). MIT is committed and will continue to serve its existing and new customers with great service and support. MIT will continue to explore other…
